MRK vs NVS
Merck & Co. vs Novartis AG — AI-powered side-by-side comparison
| Metric | MRK | NVS |
|---|
| AI Score |
70
|
75
|
| Price |
$130.34
|
$154.64
|
| P/E Ratio |
103.53×
|
23.55×
|
| ROE |
34.7%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
74.3%
|
| Debt / Equity |
1.29×
|
1.18×
|
| Dividend Yield |
2.6%
|
2.9%
|
| RSI (14) |
64.5
|
57.7
|
| Beta |
0.207
|
0.462
|
| Expected Upside |
—
|
+2.4%
|
AI Committee View
Current Innellis committee reasoning for MRK versus NVS.
NVS leads by 5 points.
NVS scores 75/100 (Buy) versus MRK at 70/100 (Buy).
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical